cute myocardial infarction (AMI) is associated with increased short-and long-term mortality. 1 The development of left ventricular (LV) dysfunction complicating an AMI is particularly serious because these patients have a several-fold increase in the risk of mortality compared with AMI survivors without LV dysfunction, 1,2 or compared with nonischemic heart failure (HF). 3 The risk of LV dysfunction is greatest in the first few days after AMI. Studies have demonstrated that patients undergoing treatment for an initial AMI have a 22% incidence of acute HF during hospitalization, and the incidence in patients with recurrent myocardial infarction (MI) is 33%. 4,5 Because of the high incidence of acute HF early after acute MI, the Circulation Journal Vol.71, August 2007 emphasis of previous studies has been on the predictors and outcomes of HF immediately following MI.
Background Although ischemic heart failure is a major cause of mortality after acute myocardial infarction (AMI), the factors that may influence the nonrecovery of left ventricular function (LVF) after an AMI are still unclear. The aim of this study was to identify predictors of nonrecovery of LVF in patients with left ventricular (LV) dysfunction (defined as an echocardiographic ejection fraction (EF) <40%) complicated with AMI who undergo successful primary percutaneous coronary intervention (PCI). Methods and Results LVF recovery was defined as improvement of LVEF more than 10% compared with baseline LVEF at follow-up. One hundred and eight patients with LV dysfunction after AMI were divided into 2 groups according to the LVF recovery at follow-up: patients with LVF recovery (n=64) vs patients without LVF recovery (n=44). The follow-up LVEF was measured at 8±4 months after PCI. Patients without LVF recovery were older (76±13 years vs 59±14 years, p=0.023) and the baseline peak monocyte count, creatine kinase, and troponin I levels were significantly higher in patients without LVF recovery than in patients with LVF recovery. Delta LVEF (follow-up LVEF -baseline LVEF) correlated with baseline peak monocyte count (r=-0.417, p<0.001), baseline peak creatine kinase (r=-0.269, p=0.005), and baseline peak troponin I levels (r=-0.256, p=0.007). Multivariate analyses showed that baseline peak monocyte count and old age were the independent predictors of nonrecovery of LVF (hazard ratio; 3.38, 95% confidence interval (CI): 1.16-5.43, p=0.012, and hazard ratio; 2.38, 95% CI: 1.09-4.87, p=0.025, respectively). Conclusion Peripheral monocytosis is associated with nonrecovery of LVF in patients with LV dysfunction complicating an AMI who underwent successful primary PCI. These results suggest an important role of monocytes in the expansion of the infarct and the development of chronic ischemic heart failure after reperfusion therapy. We excluded patients with baseline LVEF >40%, prior MI, prior LV systolic dysfunction, subacute or late stent thrombosis, restenosis after stenting, use of thrombolytic therapy prior to the present admission, coronary artery bypass graft failure, chronic renal failure, advanced liver disease, malignancies, and concomitant infectious diseases. The diagnosis of AMI was according to a consensus document of the Joint European Society of Cardiology/American College of Cardiology Committee for the Redefinition of Myocardial Infarction. 12 Infarct-related arteries were identified using a combination of ECG findings, LV wall motion abnormalities on echocardiography and coronary angiography findings.
Laboratory Analysis
Blood sampling was performed carefully and gently to avoid hemolysis. Total white blood cells and each fraction were measured with an automated hematology analyzer (Coulter Gen S, Beckman Coulter, USA) on admission and every 24 h for at least 3 days. Serum samples were stored at -70°C and were later analyzed to determine creatine kinase (CK), troponin I, and high-sensitivity C-reactive protein (hs-CRP) levels. Plasma CK and troponin I levels were measured on admission, and at 1, 6, 12, 24, and 48 h after PCI; hs-CRP was assessed by the immunoturbidimetric C-reactive protein-Latex (II) hs assay using an Olympus 5431 autoanalyzer, following the manufacturer's protocol, which has been validated against the Dade-Behring method. 13 In all patients, serum was collected the day after primary PCI for measuring lipid profiles. The serum levels of total cholesterol, triglycerides, low-density lipoprotein (LDL)-cholesterol, and high-density lipoprotein-cholesterol were measured by standard enzymatic methods. Serum levels of all these parameters were measured at baseline and at follow-up.
LVF Recovery
Echocardiography was performed before or shortly after primary PCI and at follow-up (8±4 months after PCI). LVEF was measured by Simpson's method and LVF recovery was defined as an improvement in the LVEF at follow-up of more than 10% when compared with baseline LVEF. 14 
PCI and Medications
Coronary angiography was performed through the femoral artery. All 108 infarct lesions were treated with baremetal stent implantation. Dalteparin was administered 120 units/kg body weight intravenously every 12 h, or unfractionated heparin as an intravenous bolus (usually 5,000 units) followed by a continuous infusion at a dose adjusted according to the aPTT. After PCI, all patients received aspirin (100 mg daily, indefinitely) and ticlopidine (250 mg daily continued for at least 6 months) or clopidogrel (75 mg daily continued for at least 6 months). 76 patients were treated with angiotensin-converting enzyme inhibitors, 89 were treated with -blockers, and 71 were treated with statins after PCI. Medications were assessed at baseline and every 4 weeks during clinic examinations. Medications, exact dates of initiation and cessation, and doses were recorded.
Statistical Analysis
The Statistical Package for Social Sciences (SPSS) for Windows, version 11.0 (Chicago, IL, USA) was used for all analyses. Continuous variables are presented as the mean value ± SD; comparisons were conducted by Student's t-test or nonparametric Wilcoxon test if normality assumption was violated. Discrete variables are presented as percentages and relative frequencies; comparisons were conducted using the chi-square test or Fisher's exact test as appropriate. Pearson's correlation coefficient was used to evaluate the correlations between ∆LVEF (follow-up LVEF -baseline LVEF) and baseline peak monocyte count, peak CK, peak troponin I, hs-CRP, and lipid profiles. Logistic regression analysis was used to identify the independent predictors of LVF nonrecovery. A p-value <0.05 was considered statistically significant.
Results

Baseline Clinical Characteristics and Angiographic Findings
Follow-up ejection fraction (EF) was 58±7% in patients with LVF recovery and 38±7% in patients without LVF recovery. Patients without LVF recovery were older and more had an anterior wall MI compared with patients with LVF recovery. Cardiogenic shock occurred more frequently in patients without LVF recovery compared with patients with LVF recovery. Beta-blockers and statins were less frequently used in patients without LVF recovery compared with patients with LVF recovery (Table 1) . The left anterior descending artery was involved more frequently in patients without LVF recovery compared with patients with LVF recovery (Table 2) .
Laboratory Findings
The baseline peak monocyte count and the peak CK, peak troponin I and hs-CRP levels were significantly higher in patients without LVF recovery compared with patients with LVF recovery. At follow-up, the monocyte count and the hs-CRP, and LDL-cholesterol levels were decreased in both groups. At follow-up, the monocyte count and the hs-CRP, and LDL-cholesterol levels were significantly higher in patients without LVF recovery compared with patients with LVF recovery (Table 3) .
Parameters Correlating With ∆LVEF
Delta LVEF correlated with baseline peak monocyte count (r=-0.417, p<0.001) and baseline peak CK (r= -0.269, p=0.005), and baseline peak troponin I (r=-0.256, p=0.007) levels, but not with baseline hs-CRP and baseline LDL-cholesterol levels (Fig 1) .
Predictors of Nonrecovery of LVF
Univariate predictors of the nonrecovery of LVF at follow-up were baseline peak monocyte count, age >70 years, not taking statins or -blockers, and the baseline CK level 
Discussion
This study identified factors that are important for nonrecovery of LVF in patients with LV dysfunction complicating an AMI after undergoing successful primary PCI. The baseline peak monocyte count was significantly higher in patients without LVF recovery compared with patients with LVF recovery and the change in LVEF correlated with baseline peak monocyte count. Independent predictors of nonrecovery of LVF included baseline peak monocyte count and old age.
Patients who develop HF after surviving AMI have a markedly increased risk of death compared with patients who do not develop HF, 1,2 or compared with patients with nonischemic HF. 3 The Cholesterol And Recurrent Events (CARE) trial 15 reported several factors that are important independent predictors of HF development in long-term MI survivors, including 4 historical variables (age, history of hypertension, history of MI, and diabetes mellitus), 1 physical examination variable (heart rate), 1 hemodynamic variable (EF), and 1 behavioral characteristic (exercise level). In that study, the impact of developing HF on the risk of death in patients surviving a minimum of 3 months after MI was more than 10-fold higher than in patients not developing HF.
Halkin et al reported that the predictors of LVF recovery at 7-month follow-up in patients with AMI treated with primary PCI were: no history of previous MI, depressed LVEF during the index PCI, spontaneous reperfusion before PCI, and the degree of restenosis of the infarcted artery. 16 In the present study, there was no significant difference in the restenosis rate between patients with and without LVF recovery at follow-up (31.3% vs 34.1%), and restenosis of the infarct-related artery was not an independent predictor of the nonrecovery of LVF. Although primary PCI is the most effective treatment strategy of reperfusion for AMI and stent implantation is beneficial in regard to restenosis, PCI per se does not enhance recovery of LVF. Several studies have demonstrated a relationship between peripheral monocytosis and LVF recovery. Maekawa et al 10 studied 149 patients with first Q-wave AMI to determine the significance of peripheral monocytosis in clinical outcome after reperfused AMI. Their patients with HF had higher peak monocyte counts than those without HF, and the peak monocyte count positively correlated with LV end-diastolic volume and negatively correlated with EF; a peak monocyte count >900 /mm 3 was an independent determinant of HF and cardiac events. Mariani et al 11 reported that peripheral monocytosis was independently associated with contractile recovery of the infarcted area at 6-month follow-up of 238 AMI patients treated with successful primary PCI. These 2 previous studies both included AMI patients with and without LV dysfunction after successful reperfusion therapy and both suggested a possible role of monocytes in LV remodeling after reperfused AMI. The results of the present study concur with those studies, but unlike them, we included not all AMI patients but only those with LV dysfunction (EF <40%) complicating an AMI after successful reperfusion by primary PCI. In fact, we focused on the contractile recovery in patients with LV dysfunction. In the present study, baseline and follow-up peak monocyte counts were significantly higher in patients without LVF recovery compared with patients with LVF recovery, and the change in LVEF correlated with baseline peak monocyte count, which was an independent predictor of the nonrecovery of LVF. Our results suggest an important role of monocytes in expansion of the infarct and the development of chronic ischemic HF after successful reperfusion in patients with LV dysfunction complicating an AMI. However, it is unclear if monocytosis is a cause or an effect of a larger infarct or infarct expansion that leads to LV remodeling. Actually, in the present study more patients had an anterior wall AMI and cardiogenic shock was observed more frequently in patients without LVF recovery compared with patients with LVF recovery. So, a large infarct may enhance cytokines or chemokines to induce monocyte migration into the infarcted region and may also enhance peripheral monocytosis; that is, the increment in the number of monocytes might be a result of a large infarct. However, it must be noted that the multiple regression analysis showed that the baseline peak monocyte count was an independent predictor of the nonrecovery of LVF, suggesting that monocytosis may have a negative action on contractile recovery of the infarcted area. After AMI, the resident macrophages in infarcts are activated and marginating monocytes localized close to the endothelium migrate into the necrotic myocardium through interaction with adhesion molecules. The macrophages and monocytes synthesize and secrete cytokines that induce peripheral monocytosis and infiltration of monocytes into the necrotic myocardium. [17] [18] [19] It is possible that monocyte-secreted cytokines would have a direct toxic effect on infarcted myocardium, inhibiting LVF recovery, and that persistent and excessive monocytosis could be deleterious for LV remodeling.
Study Limitations
The present study was retrospective, so is subject to the limitations inherent in this type of clinical investigation. Therefore, further prospective studies are needed. Second, the group sizes are relatively small for correct analyses. Third, we did not perform functional analysis of peripheral monocytes. Measurements of monocyte-related cytokines are needed to assess monocyte activation following AMI. Fourth, we did not demonstrate that increased numbers of peripheral monocytes infiltrate into the necrotic myocardium and contribute to the healing process of the infarct. Fifth, we could not precisely evaluate the effect of ACE inhibitors, -blockers or statins on peripheral monocytosis, because the dose and time from onset to initial administration of these drugs varied among the patients.
Conclusions
Peripheral monocytosis is associated with nonrecovery of LVF in patients with LV dysfunction complicating an AMI after successful reperfusion by primary PCI. Our results suggest an important role of monocytes in infarct expansion and the development of chronic ischemic HF after reperfused AMI.
